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Abstract
Background: There is emerging research detailing the relationship between balance/gait/falls and cognition. Imaging
studies also suggest a link between structural and functional changes in the frontal lobe (a region commonly associated
with cognitive function) and mobility. People with Parkinson’s disease have important changes in cognitive function that
may impact rehabilitation efficacy. Our underlying hypothesis is that cognitive function and frontal lobe connections
with the basal ganglia and brainstem posture/locomotor centers are responsible for postural deficits in people with
Parkinson’s disease and play a role in rehabilitation efficacy. The purpose of this study is to 1) determine if people with
Parkinson’s disease can improve mobility and/or cognition after partaking in a cognitively challenging mobility exercise
program and 2) determine if cognition and brain circuitry deficits predict responsiveness to exercise rehabilitation.
Methods/Design: This study is a randomized cross-over controlled intervention to take place at a University Balance
Disorders Laboratory. The study participants will be people with Parkinson’s disease who meet inclusion criteria for the
study. The intervention will be 6 weeks of group exercise (case) and 6 weeks of group education (control). The exercise
is a cognitively challenging program based on the Agility Boot Camp for people with PD. The education program is a
6-week program to teach people how to better live with a chronic disease. The primary outcome measure is the
MiniBESTest and the secondary outcomes are measures of mobility, cognition and neural imaging.
Discussion: The results from this study will further our understanding of the relationship between cognition and
mobility with a focus on brain circuitry as it relates to rehabilitation potential.
Trial registration: This trial is registered at clinical trials.gov (NCT02231073).
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Background
Falls due to balance and gait impairments are one of the
most important health and quality of life issues in the
elderly. Parkinson Disease (PD) is responsible for more falls
than any other chronic disease and imposes a heavy bur-
den on over 3 % of people over 65 years [1]. Until recently,
gait and balance were largely perceived as automated,
biomechanical processes that did not require cortical con-
trol. However, work over the past decade has demonstrated
the important relationships between balance/gait/falls and
cognition [2, 3]. In fact, 60 % of older people with cognitive
impairment fall annually, approximately twofold more than
cognitively intact peers, and the worse the cognitive defi-
cits, particularly executive dysfunction, the more often
people fall [4–6]. These studies support the notion that
mobility and cognition are connected, perhaps because
mobility relies upon common cortical-subcortical net-
works subserving cognition and balance. Executive
function, defined as a set of higher order cognitive pro-
cesses that control, integrate, organize and maintain
other cognitive abilities, is often altered in people with
PD. [7–9] Specific deficits include response inhibition,
set switching and updating of working memory [10–12].* Correspondence: kingla@ohsu.edu
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All of these executive components are required for func-
tional mobility in everyday environments and the relation-
ship between such function with balance and rehabilitation
has not been explored in people with PD [2, 13].
Imaging studies also suggest a link between structural
and functional changes in the frontal lobe (a region com-
monly associated with cognitive function) and mobility. A
recent European study of 415 older people used diffusion
tensor imaging (DTI) to show that parkinsonian signs of
slow walking speed, and falls are related to white matter
loss in the frontal cortex, but not the basal ganglia [14–16].
Likewise, a recent systematic review that included eighty-
six published studies using various imaging modalities to
relate neuroimaging to mobility reported that there were
consistent finding across imaging modalities linking frontal
lobe measures with mobility performance [17]. Specifically,
this targeted review supports an increased cortical con-
trol of gait in aging, reduced volume in several regions
of grey and white matter that relate to impaired mobil-
ity and consistent neuroimaging findings that reveal
the basal ganglia, parietal and frontal cortices and cere-
bellum are related to mobility outcomes [17]. Recent
work identifying the locomotor neural network, which
includes the i) supplementary motor area, ii) subtha-
lamic nucleus, iii) mesencephalic and iv) cerebellar
locomotor regions, also provides evidence for reduced
structural and altered functional connectivity in people
with PD [18, 19].
Though mobility and cognitive function may be re-
lated, rehabilitation of such deficits typically remains
separate. There is some evidence that cognitive training
may improve motor function and that mobility training
may improve cognitive function in the elderly but a re-
cent meta-analysis on this topic revealed limited and
low quality studies [20]. Although many individual stud-
ies of exercise and rehabilitation interventions report
success in improving balance and gait in people with
PD, the overall effect size of many interventions are
sometimes minimal, often not reaching the minimally
important change and/or minimal detectable change
levels [20–25]. The limited success of rehabilitation
treatment for mobility problems in people with PD may
be because current physical therapy treatment does not
directly address deficits related to frontal cortex dys-
function, such as cognition and cognitive control of bal-
ance and gait.
We recently documented that rehabilitation using the
Agility Boot Camp (ABC) training resulted in multiple
improvements in mobility such as turning, gait speed,
sit-to-stand, and balance in people with PD. [26] With
our increasing interest in the interaction of cognition
and mobility, we adapted the ABC program to incorpor-
ate additional cognitive, particularly executive function,
challenges known to be impaired in people with PD,
now called Agility Boot Camp-Cognition (ABC-C). The
purpose of this study is to 1) determine if people with
PD can improve mobility and/or cognition after partak-
ing in the ABC-C program compared to a control inter-
vention of education and 2) determine if cognition and
postural, cognitive, and brain posture/locomotor cir-
cuitry deficits predict responsiveness to the cognitively
challenging Agility Boot Camp (ABC-C) rehabilitation.
Our underlying hypothesis is that frontal lobe connec-
tions with the basal ganglia and brainstem posture/loco-
motor centers play a large role in postural deficits in
people with PD and that postural impairments will be
related to executive cognitive impairments. We will also
determine which postural, cognitive and circuitry im-
pairments predict efficacy of cognitively-challenging
mobility rehabilitation.
Methods/design
The study is a cross-over, randomized, controlled trial de-
sign to determine responsiveness to the ABC-C exercise
program. The study will include 120 people with PD (Fig. 1).
People will be randomized into either an exercise (case) or
education (control) 6-week intervention period. They will
cross over after 6 weeks to receive the other treatment.
Both interventions were designed to have the same fre-
quency and will be delivered by the same exercise trainers
for all sessions. Preceding the interventions, all patients
will be tested on multiple measures of mobility cognition,
and imaging. This same battery of tests will be administered
after 6 weeks of intervention before the participants cross
over into the second intervention. A final assessment will
occur at the end of the second and final treatment arm
(Table 2). All other interventions (medication, other inter-
ventions, exercise) will be kept as stable as possible and any
changes in medication will be monitored. This trial is regis-
tered at clinical trials.gov (NCT02231073) and OHSU eth-
ics committee has approved all aspects of the study. All
research is in compliance with the Helsinki Declarations.
Participants
Inclusion criteria for PD recruitment are a) ages 50–90
years old, without major musculoskeletal or peripheral or
central nervous system disorders (other than PD) that
could significantly affect their balance and gait, b) no re-
cent changes in medication, excessive use of alcohol or
recreational drugs, c) no history of structural brain disease,
active epilepsy, stroke or acute illness, factors affecting gait
such as severe joint disease, weakness, peripheral neur-
opathy with proprioceptive deficits, severe peripheral vas-
cular occlusive disease, severe musculoskeletal disorders,
uncorrected vision or vestibular problems, or dementia
that precludes consent to participate or ability to follow
testing procedures, d) ability to stand or walk for 2 min
with or without an assistive device, e) no medical
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condition that precludes exercise, f ) no claustrophobia, se-
vere tremor, or any health history (implanted devices,
Deep Brain Stimulation, etc.) that would interfere or put
the subject at risk near the powerful magnetic field of the
MRI scanner. Though the majority of participants will
have the diagnosis of idiopathic PD a subset of people with
frontal gait disorder may be included for pilot data ana-
lysis. Participants will also be assessed at baseline on the
Montreal Cognitive Assessment as a global screening of
cognition. All subjects will be tested at Oregon Health &
Science University. All subjects will sign an informed con-
sent and no minors will be included in the study.
Idiopathic PD inclusion criteria
The United Kingdom Brain Bank criteria will be used. i.e.,
bradykinesia and at least one of the following: rest tremor
(4–6 Hz), muscular rigidity, and postural instability not
cause by visual, vestibular, cerebellar or proprioceptive dys-
function. Three or more of the following must be present
for diagnosis of idiopathic PD: unilateral onset, rest tremor,
progressive, persistent asymmetry, excellent response to
levodopa, levodopa-induced dyskinesia [27]. All PD sub-
jects will be Hoehn and Yahr Levels II-IV and responsive
to levodopa.
Sample Size
We computed power to detect differences between the
intervention arms in a crossover trial via analysis of
variance with level of significance set to 0.05 (SAS soft-
ware v9.3). We assumed baseline levels and patterns of
change similar to those reported in King 2013 [28]. We
examined the significance of treatment effect from 1000
simulated replications of a crossover trial. The trial is
comfortably powered (85 %) with 120 patients if total
Mini-BESTest score increases by 2.4 points on average
in the ABC arm, and only 1.3 points on average in the
control arm. We predict a roughly 20 % drop-out rate,
which is conservative based on our previous experience
with short duration trials of rehabilitation in PD and by
others [24, 25, 28, 29].
Randomization and blinding
Subjects will be randomly assigned per centralized data-
base; Research Electronic Data Capture (REDCAP) to
either Education (ED) or Exercise (EX) first after pass-
ing the phone screening procedure. A computerized
block randomization in will be centrally held in the redcap
database-scheduling mode. Randomization will be imple-
mented by an independent statistician using a block size of
twelve subjects. The exercise trainer (unblinded) will notify
the subjects by phone. The researchers who will be per-
forming all pre, mid and post-tests will remain blinded to
group assignment throughout the duration of the study.
Intervention
Exercise
Subjects will participate in an 80-minute, group (6 per
group) exercise session led by a certified exercise trainer
knowledgeable in the ABC-C program for 3 days per week
for 6 weeks. Trained research assistants will spot partici-
pates with high fall risk. Although the literature does not
provide a clear dose–response for balance exercise inter-
vention, there is consensus that a challenging program at
higher doses (at least 2×/week) will show improvement
[30, 31]. The exercise protocol is an adaptation of our
ABC exercise program for PD (Table 1) [26] The theoret-
ical basis for ABC is based on research from our laboratory
and others that identified the primary neurophysiological
and cognitive constraints that limit balance and mobility in
PD [26, 28]. The exercises are designed as a circuit to
Fig. 1 Consort diagram
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challenge movement-skills known to be impaired in PD.
Stations will include: (1) Gait training (2) PWR Moves ©
[32], (3) Agility course, (4) Lunges, (5) Boxing and (6) Tai
Chi [33]. Each activity was chosen for its inherent focus on
multi-directional movements, dynamic postural transi-
tions, axial mobility, big movements and whole body
motor sequencing. Each station is engaged for 10–20 mi-
nutes with rest periods in between stations. Each station is
systematically progressed from beginning to intermediate
to advanced levels by challenging: (1) divided attention
with secondary cognitive tasks, (2) response inhibition, (3)
limiting external sensory cues, (4) increasing speed and
resistance.
Education
The Education program is a chronic disease education
program to teach patients how to live better with their
chronic condition. It was developed by our research
team to be specific for people with PD. It will include
content and discussion of topics such as sleep, nutrition,
and medication management (Table 1). Classes will con-
sist of a group of subjects (up to 6) meeting with the
trainer for 90-minute session, once a week for six weeks.
In order to match dose of the education intervention
with the exercise intervention, participants will be pro-
vided relaxation tapes to be used at home 5 times per
week for 30 minutes for an overall education dose of
240 minutes; similar to the exercise dose [34].
Compliance will be recorded at each session by the
exercise trainer for both exercise and education. For the
education arm, participants will record compliance for
the relaxation sessions in a logbook. The trainer will
code progression of exercise difficulty at the end of each
week to determine the level of exercise progression for
each person. Additionally, participants will state the
level of perceived exertion (0–10 scale) after each exer-
cise session. People will also wear hear rate monitor
during class in order to assess the aerobic level of work
being performed during exercise.
Assessment procedures
All people who are eligible per phone screening will
come into the clinic for the informed consent process.
An investigator will verbally explain the consent form,
allow the person ample time to ready through the con-
sent form and then will acknowledge consent by signing
the form. All subjects will first read and sign consent
forms. All outcomes will be measured in the practical
OFF levodopa state (12 hours withdrawal). At baseline,
people will be assessed on imaging, mobility and cogni-
tive measures and will repeat the mobility and cognitive
measures after the 1st six-week intervention and again
after the 2nd six-week intervention (Table 2).
Primary outcome measure – Mini-BESTest
The primary outcome measure on which the interven-
tion study was powered is the clinical Mini-BESTest.
[35] The Mini-BESTest [35] is a sensitive measure of dy-
namic balance and includes 14 items (a maximum and
best score of 28) [36, 37].
Table 1 Overview of exercise and education interventions
EDUCATION EXERCISE
Frequency One 90 min session/week, five 30 min relaxation
sessions/week at homeTOTAL: 240 min/week
of education and relaxation
Frequency Three 80 min sessions/week: TOTAL: 240 min/week of exercise
Topic Goal Station Time Goal Progression
Resources Topic: Finding information on PD,
communicating effectively with




10 Warm up, big steps, arm
swing
Speed, UE support (poles),
cues for big steps, ankle
weights, cognitive task
Sleep, Fatigue, Pain Topic: Solutions to common sleep, pain
and fatigue problem in PD.
PWR!
Moves
20 Aerobic, whole body
sequencing, amplitude
training
3 levels of difficulty
Nutrition Topic: Healthy eating guidelines, normal








Topic: Solutions to common emotional ups
and downs that accompany chronic illness.
Agility 10 Turns, multi-directional,
cognitive task
Speed, cognitive task
Communication Topic: Improving communication
(verbal, voice tone and body language).





Medication Topic: Purposes, effects and responsibilities
of common PD related medication.
Tai Chi 15 Weight shifting, limits of
stability, postural responses,
step initiation
3 levels of difficulty
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Secondary outcome measures
Secondary measures for clinical measures, mobility (gait
and balance), cognition and imaging domains are listed
in Table 2.
Clinical Measures
Our clinical tests will include assessment of quality of
life, balance confidence, disease severity and freezing of
gait. Specifically, the Parkinson Disease Questionnaire-
39 (PDQ-39) [38] will be used for quality of life, the
Activities-Specific Balance Confidence Scale (ABC) [39]
will be used for balance confidence, the Movement
Disorders Society Unified Parkinson’s Disease Rating
Scale ( MDS UPDRS-Motor- Parts 1-IV) will be used to
measure disease severity [13, 40] and the new freezing of
gait questionnaire will be used as a self assessment of
freezing of gait [41].
Mobility Testing
All secondary measures of mobility come from perform-
ance of tasks while subjects are instrumented with
body-worn, inertial sensors. Specifically, eight wireless,
synchronized, Opal inertial sensors (APDM, Inc) will be
applied with elastic Velcro bands to both feet, ankles
and wrists, as well as the lumbar spine and mid sternum
of the torso. Inertial sensor data collected at 128Hz will
be wirelessly transferred to a laptop for automatic gen-
eration of gait and balance metrics by Mobility Lab and
raw data for further analysis with Matlab [42]. Partici-
pants will perform tasks of quiet stance, the 2-minute
walk test and the 360-degree turn test with and without
a secondary, cognitive task (Table 2). All participants
will wear a safety belt during the walking tasks and a
trained research assistant will walk along side the par-
ticipants. If a participant loses his or her balance, the re-
search assistant will assist and prevent a fall. All safety
measures will be taken to ensure a secure and comfort-
able environment. To prevent fatigue, participant will
be repeatedly reminded that he or she may take a break
whenever needed.
Cognitive testing
Participants will complete a battery of cognitive tests to
assess several dimensions of cognition. A table of all





MDS-UPDRS All sections of the Unified Parkinson’s Disease Rating Scale will be used to measure related
to severity of PD.
NFOGQ The New FoG of Gait Questionnaire will be used to identify ‘freezers’ (score >3).
Activities of balance confidence (ABC) The ABC measures how balance confidence limits participating in the community.
PDQ-39 This 39 item questionnaire measures multiple domains of quality of life.
Mobility
Balance Postural sway during 30 seconds of quiet stance with and without cognitive task
Turning Smoothness of turning measured during the 1 min turning in place (360 degree turning
in place) and turns during the 2 min walk with and without a cognitive task.
Gait Spatial and temporal gait metrics during walking with and without dual task
Imaging
High angular resolution diffusion imaging High angular resolution diffusion imaging to assess white matter microstructure. Structural
connectivity of the locomotor network will be assessed using probabilistic tractography.
rsfcMRI An indirect assessment of communication between spatially disparate neural regions.
Analysis is restricted to neural regions comprising the locomotor network including
the supplementary motor area, subthalamic nuclei, mesencephalic locomotor regions
(pedunculopontine and cuneiform nuclei), and the midline cerebellar locomotor region
Cognition
General Scales for outcome of Parkinson’s
Disease-Cognition (SCOPA-COG)
An instrument that was designed to assess the specific ‘frontal-subcortical”
cognitive deficits found in Parkinson’s disease
Inhibition Stroop task, flankers, Go/nogo, Stop
signal task
The ability to deliberately inhibit dominant or prepotent responses when appropriate.
Shifting Set-Shifting, Trail making task The ability to flexibly alter behavior when relevant changes occur in the predefined
goal or in the environment.
Updating Dot counting task The ability to update and monitor working memory representations.
Visuospatial Benton judgment of line orientation test The ability to identify a stimulus, its orientation, and its location.
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cognitive tests and a brief description is presented in
Table 2. Most tests are categorized into the three domains
of executive function defined by Miyake and colleagues
(2000): inhibition (Stroop color-word test, Flankers, Go/
NoGo, Stop Signal Reaction Time Test) [43–46], set shifting
(Trail Making, Shifting Task) [45, 47–49] and updating or
working memory (Dot Counting Test) [45]. We will also as-
sess general cognition for people with PD via the Scales for
Outcome of Parkinson’s Disease-Cognition (SCOPA-COG)
and Montreal Cognitive Assessment (MoCA) [50, 51]. In
addition, visuospatial function (Benton Judgement of Line
Orientation) will be assessed.
Imaging
The subject will be led into the MRI magnet room and
positioned on the MRI system bed. A 32-channel Sie-
mens rf-receiver coil will be placed appropriately for
brain MRI, and the subject will be loaded into the mag-
net. During imaging, the subject’s head will rest on a
special neck and head pillow to minimize head move-
ments. Extra pillows under the knees and back will be
used to make subjects as comfortable as possible. They
will wear headphones to dampen noise during imaging
and to allow subjects to hear and talk to the investiga-
tors at all times. Our procedures do not include admin-
istration of MRI contrast agents. The following protocol
will then be executed:
Imaging data will be acquired using a 3.0 T Siemens
Magnetom Tim Trio scanner with a 12-channel head coil.
We will collect one whole brain high-resolution structural
T1-weighted MPRAGE sequence (sagittal, TE = 3.58 ms,
TR = 2300 ms, 256 x 256 matrix, resolution = 1 mm3, 1
average, total scan time = 9 min-14 s). We will also collect
high angular resolution diffusion imaging using an echo-
planar imaging sequence (72 different gradient directions,
b-value = 3,000 mm/s2, TR = 7100 ms, TE = 112 ms,
2.5 mm3 voxels, 48 slices, FOV= 230 × 230 mm). Finally,
we will acquire a resting-state functional MRI (rs-fMRI)
using a gradient-echo echo-planar imaging sequence
(TR = 2500 ms, TE = 30 ms, FA = 90°, 3.8 mm3volexs,
36 slices with interleaved acquisition, FOV = 240 ×
240 mm). We will acquire two 10-minutes runs, pro-
viding a total of 20 minutes of resting state data for
each subject in the study. Subjects will be instructed to
lie still and keep their eyes open. Head padding will be
provided to help subjects keep their heads still, ear-
plugs will protect against scanner noise, and a leg bol-
ster will be provided for back comfort. The technician
will monitor the data and collect an extra scan if head
movement > 1 mm is apparent.
Statistical Analysis
First, we will compare the amount of improvement in the
Mini-BESTest with an analysis of covariance (ANCOVA)
model, controlling for age. It is possible that lower func-
tioning patients will have larger adaptation to ABC-C since
they start out with less function. Alternatively, it is possible
that the lower functioning patients will have poorer exer-
cise tolerance so will improve less so we will also control
for baseline Mini-BESTest. Because we are utilizing a
crossover design, the treatment effect will represent change
during the ABC-C versus control rehabilitation periods re-
gardless of whether a patient received the ABC-C interven-
tion during period 1 or period 2. We will assess, but do
not anticipate, period by treatment group interaction ef-
fects. We will also enter an interaction term into the model
to assess for differential intervention effects cognitive and/
or frontal lobe structural and functional connectivity sta-
tus. Second, we will relate the percent improvement in the
Mini-BESTest with ABC-C intervention with baseline
measures of posture/gait impairments, cognitive impair-
ments and both structural and functional connectivity of
the Posture/Locomotor circuit at baseline with linear re-
gression models. Previous studies have shown the Minimal
Detectable Change of the Mini-BESTest was 3 points [52].
We will also determine how many subjects move from
high- to low-fall risk; a cutoff score for identifying PD
fallers from non-fallers with the Mini-BESTest is 19/28
(63 %), with a sensitivity of .98 in 80 subjects [53].
Discussion
The overarching goal of this study is to determine if cog-
nitive function and frontal brain circuitry deficits predict
responsiveness to exercise. Specifically, we are interested
in understanding if certain phenotypes that best predict
responsiveness to high intensity, short duration agility
rehabilitation with a focus on cognition will help guide
therapists to identify candidates for therapy and to de-
velop specific therapy for specific types of mobility dis-
abilities from parkinsonism. To date, there are very few
studies on cognitive contributions to gait and balance as
they relate to rehabilitation, particularly in this challen-
ging population. Currently, physical therapists do not
routinely incorporate cognitive challenges for people
with PD and furthermore, it is unclear if these patients
will benefit from such training.
If we find that executive function deficits and reduced
structural and/or functional connectivity of the loco-
motor circuitry predict poor responses to challenging
balance rehabilitation, that supports our hypothesis that
frontal (and prefrontal) lobe impairments limits re-
habilitation efficacy. If particular impairments of bal-
ance and gait improve more than others with ABC-C,
this information will be used to improve the ABC-C
intervention and will be followed by studies focused on
determining which postural domains are most amen-
able to improvement with rehabilitation. The results
from this study will further our understanding of the
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relationship between cognition and mobility with a
focus on brain circuitry as it relates to rehabilitation
potential.
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